FDA
11 documents
Comments on guidance and policy, responses to citizen petitions, and nominations to the 503B bulk drug substances list.
February 13, 2025
Petition
Opposed Novo Nordisk’s citizen petition on OFA’s nomination of semaglutide to the 503B bulks list
November 15, 2024
Comment
Commented to FDA on the semaglutide shortage
October 31, 2024
Comment
Urged FDA to weigh stakeholder input to build a full understanding of outsourcing facilities


